Bio
Dr. Cong's research group at the Department of Pathology and Department of Genetics is developing technology for genome editing and single-cell genomics, using computational approaches inspired by data science. His group has a focus on using these tools to study immunological and infectious diseases. His work has led to one of the first FDA-approved clinical trials employing viral delivery of CRISPR/Cas9 gene-editing for in vivo gene therapy. More recently, his group has invited high-efficiency tools for large-scale genome engineering based on novel microbial proteins, and developed single-cell analysis approach with applications in cancer biology and immunology. Dr. Cong is a recipient of the NIH/NHGRI Genomic Innovator Award, a Baxter Foundation Faculty Scholar, and has been selected by Clarivate Web of Science as a Highly Cited Researcher.
